Cefepime-Induced Neurotoxicity in a 74-Year-Old Woman

Samanvaya Sharma 1, Muzammil Khan 2, Muhammad Owais 3, Asim Haider 4

1. Internal Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, USA
2. Internal Medicine, Stony Brook University Hospital, Stony Brook, USA
3. Respiratory Medicine, Rush University Medical Center, Chicago, USA
4. Internal Medicine, BronxCare Health System, New York, USA

Corresponding author: Asim Haider, asim.haider164@gmail.com

Abstract

Cefepime is a fourth-generation cephalosporin with anti-pseudomonal coverage. It has been known to cause neurotoxicity, especially in critically ill patients and those with renal impairment. This neurotoxicity is poorly characterized and under-recognized. We present a case of cefepime-induced neurotoxicity in a 74-year-old woman being treated for cellulitis and osteomyelitis. Symptoms were gradual in onset and included confusion, verbal perseveration, and myoclonus. EEG findings included generalized periodic discharges (GPD) and generalized rhythmic delta activity with admixed sharps (GRDA + S). Symptoms resolved one to two days after the cessation of cefepime and anti-epileptic therapy with lorazepam, topiramate, and levetiracetam. We follow this with a discussion of available literature and recommend regular therapeutic drug monitoring in the future.

Categories: Internal Medicine, Neurology, Infectious Disease
Keywords: electroencephalogram, cephalosporin, seizures, cefepime, neurotoxicity

Introduction

Cefepime is a fourth-generation cephalosporin, a well-known broad-spectrum antibiotic with antipseudomonal coverage and some resistance to beta-lactamases. It was made commercially available in 1994 [1]. Since 1999, it has been known to cause neurotoxicity, a side-effect that is under-recognized and poorly studied. We present here a case of cefepime-induced neurotoxicity (CIN) followed by a discussion of its salient features with the associated literature. It is our hope that our work will contribute to a greater awareness of CIN, ultimately curbing the associated morbidity for patients.

Case Presentation

A 74-year-old woman with a history of peripheral vascular disease, stage 3b chronic kidney disease, type 2 diabetes mellitus, and anxiety presented to the emergency room for urgent management of a foot ulcer and associated cellulitis upon the recommendation of her vascular surgeon in the clinic. She had been complaining of severe pain at the site worsening over the course of one week. The review of systems was otherwise negative. Vital signs were within normal limits. On examination, her wound revealed an exposed tendon with a malodorous necrotic soft tissue base. The laboratory findings are given in Table 1.

| Laboratory parameter         | Laboratory value       |
|------------------------------|------------------------|
| Erythrocyte sedimentation rate | 45 mm/hr (Range: 0 to 29 mm/hr) |
| C-reactive protein           | 0.9 mg/dl (Range < 0.3 mg/dl) |
| Blood urea nitrogen          | 47 mg/dl (range: 6-24 mg/dl) |
| Creatinine, Serum            | 1.3 mg/dl (Range: 0.7-1.5 mg/dl) |
| White blood cells            | 5.1 k/ul (range: 4.8-10.8 k/ul) |

TABLE 1: Laboratory findings

A foot radiograph and CT ruled out fracture and gas gangrene. A foot MRI identified multiple foci suggestive of osteomyelitis. The patient was started on empiric cefepime 2g Q12H and vancomycin for cellulitis and osteomyelitis, methicillin, ceftriaxone, and pro re nata (PRN) morphine for analgesia, fluids for prerenal acute-on-chronic kidney injury, and admitted for further management as per podiatry and vascular surgery recommendations. Wound culture was positive for Klebsiella oxytoca (sensitive to cefepime),...
Serratia liquefaciens (sensitive to cefepime), and alpha-hemolytic Streptococci (Viridans group). Blood cultures were positive for coagulase-negative staphylococci. An antibiotic regimen was continued as initiated.

On day two of the hospital course, the patient was found to be confused and delirious. A finger stick blood glucose test was 41 mg/dL, prompting the administration of dextrose 50 in water leading to improvement in mentation. Her basal insulin regimen was accordingly adjusted. A few hours later, however, the patient was found to be confused again, repeatedly saying her first name in response to all questions and unable to follow any instructions. This time, her fingerstick glucose test was normal. A non-contrast head CT and a CT angiogram of the head and neck ruled out any acute cerebrovascular pathology (Figure 1).

These findings were confirmed with an MRI. The patient then went on to develop rigidity in all four extremities - more severe on the right - with mimicking and automatisms, followed by a rapid return to baseline in two to three minutes. She was started on continuous EEG with video monitoring, identifying generalized background slowing, and rare, very brief runs of generalized rhythmic delta activity (GRDA) over the course of 24 hours. However, given the high risk of seizure with old infarcts and ongoing infection, she was started on levetiracetam 500 mg Q12H for seizure prophylaxis. The leading etiology of the patient’s altered mental status at this time was suspected to be polypharmacy. Her pain regimen was accordingly adjusted, lowering the frequency of methocarbamol, gabapentin, and PRN morphine, and discontinuing oxycodone.
the next few days in the hospital course were marked by mild confusion - the patient was disoriented to
time and would often repeat her first name unprompted - and anxiety, which improved with 2 mg of
diazepam (home dose) each day. Mental status was otherwise stable. She underwent management of her
wound as directed by podiatry and vascular surgery.

On day eight of the hospital course, the patient was not answering any questions and had fluctuating
attention. She was unable to follow commands and often stared blankly at interviewers. She was notably pale
and was breathing rapidly. She was also noted to have right upper extremity myoclonus. Vitals were
significant for tachypnea to 26 breaths/min but otherwise normal. Laboratory studies had no significant
acute changes. The patient was again placed on continuous EEG with video monitoring, revealing
continuous bursts of high voltage rhythmic 1-2 Hz generalized periodic discharges (GPD). The patient was
given lorazepam 2 mg, which broke the EEG pattern for approximately 10 hours, becoming frequent
generalized rhythmic delta activity with admixed sharps (GRDA + S). Generalized background slowing was
seen again, consistent with the previous EEG. Additionally, the patient’s levetiracetam was raised to 750 mg
Q12H and she was also started on topiramate 100 mg QD. A clinical diagnosis of cefepime toxicity was made,
and she was switched to ceftazidime 2g Q24H. Additionally, methocarbamol and PRN morphine were
discontinued, leaving only reduced-dose gabapentin for analgesia, which was a successful regimen. Delirium
precautions were undertaken.

On day nine of the hospital course, the patient’s mental status began to improve. Early in the day, EEG
revealed occasional (<9% of the record), brief bursts of GRDA + S, and occasional GPDs with sharp wave
morphology at 1 Hz. As the day progressed, there was a significant improvement, and the only significant
finding was generalized background slowing consistent with baseline. By day 10, she was conversant and
comfortable during the examination. She was continued on ceftazidime, levetiracetam, and topiramate and
had no further episodes of altered mental status during the hospital course.

Discussion

CIN is a generally under-recognized condition, leading to a paucity of data. Studies attempting to identify an
incidence rate have ranged significantly in their results. Retrospective studies of febrile neutropenic
patients with mildly impaired renal function and ICU patients showed CIN incidence rates of 20% and 15%,
respectively [2,3]. In contrast, retrospective studies attempting to find a CIN incidence rate in healthy
patients have reported numbers from 6%, 11%, and 23.2% depending on how strictly they define CIN and
how broad a section of patients they measure cefepime trough levels in [4-6].

In a systematic review of literature spanning from January 1980 (roughly corresponding to the earliest use of
cefepime) to February 2016, Payne et al. reviewed 57 qualifying publications, representing 155 patient cases
of CIN [1]. All patients reportedly had altered mental status, most commonly experiencing reduced
consciousness (47%), confusion (42%), and myoclonus (42%). Changes in mental status usually appear
before myoclonus and seizures. All patients who had EEG data had EEG abnormalities. Symptoms were often
delayed with a median onset of four days (interquartile range of two to six days). Treatment usually involved
cessation or dose- reduction of cefepime (85% of cases), and sometimes also included antiepileptic drugs -
mostly a benzodiazepine- (36% of cases) and, rarely, hemodialysis (8% of cases) [1]. Clinical improvement
was observed in a median of two days after intervention (interquartile range of one to three days). Of the
patients, 80% had renal dysfunction and 81% with a reported location were ICU patients [1].

These findings are generally reflected in our patient with a few variations. Our patient was confused and
verbally perseverating on her name on day two of her cefepime course. The cause of her symptoms was
initially suspected to be hypoglycemia, and then polypharmacy, which were both managed accordingly. An
EEG revealed background slowing and rare, very brief runs of GRDA. Given the high risk of seizure with her
old infarcts and ongoing infection, she was started on levetiracetam on the same day. Cefepime toxicity was
not highly suspected, likely due to its limited recognition. The next few days were marked with continued
confusion and verbal perseveration on occasion but relatively well-controlled symptoms. Her symptoms
exacerbated significantly on day eight of her hospital course. It is impossible to say with certainty whether
her altered mental status until this point was entirely or only partially due to cefepime toxicity. Therefore,
the onset of symptoms was anywhere between day two and day eight, a range that is likely influenced by her
seizure prophylaxis with levetiracetam. Regardless, consistent with the findings reported by Payne et al., she
clearly had a period of confusion before developing myoclonus and other motor symptoms [1]. The diagnosis
of CIN followed by the cessation of cefepime, one-dose lorazepam, and continued maintenance on
levetiracetam and topiramate led to a rapid resolution of symptoms within one to two days, as is reportedly
typical. Lastly, our patient had stage 3b chronic kidney disease, so for her to be at significant risk for
developing CIN would also be consistent with the findings of Payne et al. [1].

Boschung et al. concluded that in the patients with risk factors for developing the CIN, cefepime trough
levels should be routinely measured and maintained to be < 7.5 mg/L [6]. The clinical symptoms of CIN
include headache (<1%), aphasia (<1%) [7], confusion (<1%), encephalopathy (<1%), seizure (<1%) [8],
hallucination (<1%) [2], myoclonus (<1%) [9], status epilepticus (<1%) [10], stupor (<1%) [11], and coma (<1%)
[12]. These adverse effects can occur even with the appropriate dosing and usually resolve once the drug is
interrupted; however, some patients may require additional interventions (e.g. antiepileptic therapy or
Conclusions

We conclude by reiterating that CIN is under-recognized. When cefepime is administered to patients with renal impairment, CIN must be considered on the differential if patients develop altered mental status, myoclonus, convulsive seizures, or nonconvulsive status epilepticus. EEG findings are abnormal in every known case of CIN, and therefore clinicians should not hesitate in placing these patients on EEG monitoring upon any mental status alterations. We also recommend routine monitoring of cefepime trough levels in patients on cefepime - particularly patients with renal impairment - and we emphasize the need for prospective studies in this regard to identify a clear threshold.

Additional Information

Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, Fraser GL: Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017, 21:276. 10.1186/s13054-017-1856-1
2. Lamoth F, Buclin T, Pascual A, et al.: High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010, 54:4360-7. 10.1128/AAC.01595-08
3. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA: Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013, 17:R264. 10.1186/cc13094
4. Lau C, Marriott D, Gould M, Andresen D, Reuter SE, Penm J: A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. J Antimicrob Chemother. 2020, 75:718-25. 10.1093/jac/dkz746
5. Huyler T, Lenggenhager L, Abbas M, et al.: Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017, 23:454-9. 10.1016/j.cmi.2017.01.005
6. Boschung-Pasquier L, Atkinson A, Kastner LK, et al.: Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020, 26:333-9. 10.1016/j.cmi.2019.06.028
7. Isitan C, Ferree A, Kohler AD: Cefepime induced neurotoxicity: a case series and review of the literature. eNeurologicalSci. 2017, 8:40-3. 10.1016/j.eensci.2017.08.001
8. Triplet JD, Lawn ND, Chan J, Dunne JW: Cephalosporin-related neurotoxicity: Metabolic encephalopathy or non-convulsive status epilepticus?. J Clin Neurosci. 2019, 67:163-6. 10.1016/j.jocn.2019.05.055
9. Lizarraza KJ, Heros DO, Adams D, Lang AE, Kanner AM: Opsoclonus-myoclonus-encephalopathy induced by cefepime. J Neurol Sci. 2019, 396:53-5. 10.1016/j.jns.2018.10.028
10. Gariin A, Bavozet F: Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis. BMJ Case Rep. 2019, 12:10.1136/bcr-2018-228108
11. Kim A, Kim JE, Paek YM, et al.: Cefepime-induced non-convulsive status epilepticus (NCSE). J Epilepsy Res. 2013, 3:39-41.
12. Sonck J, Laureys G, Verbeeck D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008, 23:966-70. 10.1093/ndt/gfn715